What are the key takeaways for Catheter Precision Inc ($VTAK)?

Catheter Precision reported Q2 2026 revenue of $1,019,000, representing a robust 380.7% increase year-over-year from a low base of $212,000 in Q2 2025. The company faces severe liquidity constraints with only $643,000 in cash and cash equivalents against $11,026,000 in total debt as of June 30, 2026. Operating performance reflects persistent losses, with a Q2 2026 net loss of $2,555,000 and free cash flow burn of $2,876,000 during the quarter.

Catheter Precision Inc (VTAK) AI Stock Analysis & Earnings

Please enable JavaScript to continue using this application.

Latest Report Overview for Catheter Precision Inc ($VTAK)

AI-powered analysis of Catheter Precision Inc (VTAK) stock based on Q2 2026 financial data.

Published: October 16, 2026

Latest Report Overview

Catheter Precision Inc (VTAK) reported For the quarterly period ended June 30, 2026 (Issuer fiscal Q2 FY2026) revenue of $1 million with diluted EPS of $-0.92 and net income of -$2.6 million. Operating margin was -388.1%, and free cash flow was -$2.9 million for the period.

Key Takeaways for Catheter Precision Inc

Catheter Precision reported Q2 2026 revenue of $1,019,000, representing a robust 380.7% increase year-over-year from a low base of $212,000 in Q2 2025.
The company faces severe liquidity constraints with only $643,000 in cash and cash equivalents against $11,026,000 in total debt as of June 30, 2026.
Operating performance reflects persistent losses, with a Q2 2026 net loss of $2,555,000 and free cash flow burn of $2,876,000 during the quarter.
Gross margin experienced a notable compression down to 9.6% in Q2 2026 compared to over 90% in previous quarters, reflecting potential product mix shifts or inventory adjustments.
The company relies heavily on ongoing commercialization efforts for its proprietary cardiac electrophysiology systems, such as the Vdrive robotic navigation system and Vips non-invasive mapping system.
Given the tight cash position and high debt load, near-term capital raising, restructuring, or strategic financing alternatives remain critical risk factors for ongoing operations.

What Does Catheter Precision Inc Do?

Catheter Precision Inc is a medical device company focused on the cardiac electrophysiology market, specializing in the development and commercialization of innovative products designed to improve the diagnosis and treatment of cardiac arrhythmias. The company's core product portfolio includes advanced electrophysiology navigation and mapping tools, such as the Vdrive robotic navigation system, which allows for precise catheter manipulation, and non-invasive cardiac mapping systems designed to identify ventricular arrhythmias prior to invasive procedures. The company primarily targets electrophysiologists, cardiologists, hospitals, and specialized cardiac care medical centers operating within the healthcare sector. Its solutions are designed to enhance procedural efficiency, reduce radiation exposure, and improve clinical outcomes during complex electrophysiology interventions. Operating as a micro-cap medical device enterprise, Catheter Precision maintains a lean operational scale with limited commercial footprint relative to industry giants, relying on specialized product differentiation, clinical utility, and direct hospital engagement to carve out a niche in the competitive cardiac care landscape.

Growth Drivers for Catheter Precision Inc

Increasing commercial adoption and hospital placements of the Vdrive robotic navigation system in electrophysiology labs.
Expansion of consumable disposable product sales driven by growing procedure volumes utilizing company hardware.
Geographic market expansion and regulatory clearances for advanced non-invasive mapping technologies such as Vips.
Strategic physician education, clinical data presentations, and hospital value-analysis committee approvals.
Potential partnerships or distribution agreements to leverage broader sales channels.

Overview AI Summary Charts Financials Valuation

Based on June 30, 2026

Chartloom AI Score

AI-assisted ratings across moat, quality, capital allocation, growth, and AI opportunity vs risk.

Latest Report Overview for Catheter Precision Inc ($VTAK)

Key Takeaways

1.Catheter Precision reported Q2 2026 revenue of $1,019,000, representing a robust 380.7% increase year-over-year from a low base of $212,000 in Q2 2025.
2.The company faces severe liquidity constraints with only $643,000 in cash and cash equivalents against $11,026,000 in total debt as of June 30, 2026.
3.Operating performance reflects persistent losses, with a Q2 2026 net loss of $2,555,000 and free cash flow burn of $2,876,000 during the quarter.
4.Gross margin experienced a notable compression down to 9.6% in Q2 2026 compared to over 90% in previous quarters, reflecting potential product mix shifts or inventory adjustments.
5.The company relies heavily on ongoing commercialization efforts for its proprietary cardiac electrophysiology systems, such as the Vdrive robotic navigation system and Vips non-invasive mapping system.
6.Given the tight cash position and high debt load, near-term capital raising, restructuring, or strategic financing alternatives remain critical risk factors for ongoing operations.

What They Do

How They Make Money

Catheter Precision generates its revenue primarily through the sale of medical device hardware systems and associated single-use disposables, accessories, and proprietary software licenses used in electrophysiology laboratories. Revenue is recognized when control of the products is transferred to customers, typically upon shipment or delivery to hospitals and medical centers. The revenue model combines capital equipment placements—such as the Vdrive system—with a recurring or consumable revenue stream derived from proprietary single-use catheters and sterile accessories utilized during each procedure. This razor-and-blade model aims to secure recurring pull-through revenue once hardware is installed in hospital labs. Key drivers of revenue growth include expanding the installed base of systems, increasing procedure volumes utilizing proprietary disposables, expanding geographic market access, and securing hospital value-analysis committee approvals. While revenue has exhibited high percentage growth off a small baseline, the economic engine remains sensitive to hospital capital expenditure cycles, physician adoption rates, and reimbursement coverage.

Competitive Position

Catheter Precision operates in the highly competitive cardiac electrophysiology sector, competing against major multinational medical device conglomerates such as Biosense Webster (Johnson & Johnson), Abbott Laboratories, Boston Scientific, and Medtronic. These established competitors possess vast financial resources, extensive global distribution networks, entrenched hospital relationships, and broad product portfolios. The company claims competitive differentiators centered on the precision, ergonomic benefits, and procedural enhancements offered by its robotic and non-invasive mapping technologies, such as reducing physician radiation exposure and improving mapping accuracy for complex arrhythmias. However, relative valuation and market positioning reflect its micro-cap status, constrained cash reserves, and significantly smaller revenue scale compared to major peers. Financial trends indicate rapid percentage revenue growth but ongoing margin volatility and high cash burn, highlighting the challenges of scaling against well-capitalized incumbents. The sustainability of Catheter Precision's competitive position depends heavily on its ability to successfully execute commercial rollouts, secure necessary capital, and demonstrate compelling clinical outcomes that justify hospital adoption.

Business Strategy & Moat

Catheter Precision’s business strategy centers on driving commercial adoption of its proprietary electrophysiology portfolio, expanding physician awareness, and establishing clinical utility to penetrate hospital cardiac labs. The company's strategic flywheel relies on placing capital equipment systems to generate a sticky, recurring stream of consumable disposable sales, which in turn supports revenue scaling and validation. The company's moat type is narrow, resting primarily on specialized intellectual property and product design rather than entrenched network effects or massive scale advantages. Switching costs in hospital electrophysiology labs can be moderate once a system is integrated into clinical workflows, but incumbent giants maintain formidable barriers through comprehensive bundled product offerings. Capital allocation has been constrained by tight liquidity and substantial debt obligations, requiring management to balance essential commercialization and R&D expenditures with strict cash conservation. Given the company's fragile balance sheet, executing strategic financing or partnership transactions remains essential to sustain the strategic roadmap.

Industry Outlook

The cardiac electrophysiology and medical device sector benefits from favorable long-term demographic tailwinds, including an aging global population and an increasing prevalence of cardiovascular diseases and cardiac arrhythmias. Demand for advanced, minimally invasive surgical technologies that reduce procedure times, enhance precision, and lower radiation exposure remains robust among hospitals and electrophysiologists. However, the industry is characterized by rigorous regulatory approval processes, stringent reimbursement dynamics, and intense competition from entrenched multinational medical device manufacturers. Macroeconomic pressures, hospital capital budget constraints, and supply chain dynamics can influence purchasing decisions for capital equipment. Smaller enterprises in this sector face distinct headwinds related to capital availability, commercial scaling, and market access against dominant industry players.

Growth Drivers

•Increasing commercial adoption and hospital placements of the Vdrive robotic navigation system in electrophysiology labs.
•Expansion of consumable disposable product sales driven by growing procedure volumes utilizing company hardware.
•Geographic market expansion and regulatory clearances for advanced non-invasive mapping technologies such as Vips.
•Strategic physician education, clinical data presentations, and hospital value-analysis committee approvals.
•Potential partnerships or distribution agreements to leverage broader sales channels.

Recent Developments

•Reported Q2 2026 revenue of $1,019,000, reflecting a 380.7% year-over-year increase in quarterly sales volume.
•Continued navigation of tight liquidity constraints with cash reserves of $643,000 and total debt of $11,026,000 as of June 30, 2026.
•Ongoing commercialization efforts focused on expanding the customer base and hospital accounts for proprietary electrophysiology devices.
•Management focus on optimizing operating expenses and evaluating capital-raising alternatives to support ongoing working capital requirements.
•Ongoing clinical positioning of non-invasive cardiac mapping solutions to support physician decision-making in arrhythmia treatments.

Catalysts

•Quarterly financial reporting and ongoing revenue growth trajectory updates in upcoming earnings releases.
•Potential regulatory approvals or clearance milestones for new product iterations or international markets.
•Execution of strategic financing, debt restructuring, or capital-raising transactions to alleviate liquidity pressures.
•Expansion of hospital customer contracts and distribution partnerships accelerating product pull-through.
•Clinical data publications highlighting the efficacy and procedural benefits of Vdrive and non-invasive mapping systems.

Strengths

•High percentage revenue growth trajectory, evidenced by a 380.7% YoY increase in Q2 2026 revenue to $1,019,000.
•Innovative proprietary product portfolio addressing specialized needs in cardiac electrophysiology and arrhythmia treatment.
•Differentiated technology offerings aimed at reducing procedural radiation and enhancing catheter precision.
•Growing commercial traction and increasing hospital adoption metrics from a low baseline.
•Focused management commitment to expanding clinical utility and physician awareness in target cardiology markets.

Risks & Concerns for Catheter Precision Inc ($VTAK)

You're one step away

Unlock the full risk analysis

See business risks, AI filing insights, and deeper research for this stock. Create a free account to continue — includes a 14-day Pro trial.

No card required • Free plan stays after trial

About this summary

AI-generated research for Catheter Precision Inc (VTAK, filings period ending June 30, 2026). AI summaries, reports, and scoring can be inaccurate or incorrect; accuracy and correctness are not guaranteed. Informational only; not investment advice or personalized guidance.Enumerated risk factors in this view may be abbreviated for anonymous or guest sessions. Full risk sections are available with full access.

Summary generated on Oct 16, 2026.

Peers of Catheter Precision Inc (VTAK)

Side-by-side comparison

Latest Report Overview for Catheter Precision Inc ($VTAK)

AI-powered analysis of Catheter Precision Inc (VTAK) stock based on Q2 2026 financial data.

Published: October 16, 2026

Latest Report Overview

Key Takeaways for Catheter Precision Inc

Catheter Precision reported Q2 2026 revenue of $1,019,000, representing a robust 380.7% increase year-over-year from a low base of $212,000 in Q2 2025.
The company faces severe liquidity constraints with only $643,000 in cash and cash equivalents against $11,026,000 in total debt as of June 30, 2026.
Operating performance reflects persistent losses, with a Q2 2026 net loss of $2,555,000 and free cash flow burn of $2,876,000 during the quarter.
Gross margin experienced a notable compression down to 9.6% in Q2 2026 compared to over 90% in previous quarters, reflecting potential product mix shifts or inventory adjustments.
The company relies heavily on ongoing commercialization efforts for its proprietary cardiac electrophysiology systems, such as the Vdrive robotic navigation system and Vips non-invasive mapping system.
Given the tight cash position and high debt load, near-term capital raising, restructuring, or strategic financing alternatives remain critical risk factors for ongoing operations.

What Does Catheter Precision Inc Do?

Growth Drivers for Catheter Precision Inc

Increasing commercial adoption and hospital placements of the Vdrive robotic navigation system in electrophysiology labs.
Expansion of consumable disposable product sales driven by growing procedure volumes utilizing company hardware.
Geographic market expansion and regulatory clearances for advanced non-invasive mapping technologies such as Vips.
Strategic physician education, clinical data presentations, and hospital value-analysis committee approvals.
Potential partnerships or distribution agreements to leverage broader sales channels.

Based on June 30, 2026

Chartloom AI Score

AI-assisted ratings across moat, quality, capital allocation, growth, and AI opportunity vs risk.

Latest Report Overview for Catheter Precision Inc ($VTAK)

Key Takeaways

1.Catheter Precision reported Q2 2026 revenue of $1,019,000, representing a robust 380.7% increase year-over-year from a low base of $212,000 in Q2 2025.
2.The company faces severe liquidity constraints with only $643,000 in cash and cash equivalents against $11,026,000 in total debt as of June 30, 2026.
3.Operating performance reflects persistent losses, with a Q2 2026 net loss of $2,555,000 and free cash flow burn of $2,876,000 during the quarter.
4.Gross margin experienced a notable compression down to 9.6% in Q2 2026 compared to over 90% in previous quarters, reflecting potential product mix shifts or inventory adjustments.
5.The company relies heavily on ongoing commercialization efforts for its proprietary cardiac electrophysiology systems, such as the Vdrive robotic navigation system and Vips non-invasive mapping system.
6.Given the tight cash position and high debt load, near-term capital raising, restructuring, or strategic financing alternatives remain critical risk factors for ongoing operations.

What They Do

How They Make Money

Competitive Position

Business Strategy & Moat

Industry Outlook

Growth Drivers

•Increasing commercial adoption and hospital placements of the Vdrive robotic navigation system in electrophysiology labs.
•Expansion of consumable disposable product sales driven by growing procedure volumes utilizing company hardware.
•Geographic market expansion and regulatory clearances for advanced non-invasive mapping technologies such as Vips.
•Strategic physician education, clinical data presentations, and hospital value-analysis committee approvals.
•Potential partnerships or distribution agreements to leverage broader sales channels.

Recent Developments

•Reported Q2 2026 revenue of $1,019,000, reflecting a 380.7% year-over-year increase in quarterly sales volume.
•Continued navigation of tight liquidity constraints with cash reserves of $643,000 and total debt of $11,026,000 as of June 30, 2026.
•Ongoing commercialization efforts focused on expanding the customer base and hospital accounts for proprietary electrophysiology devices.
•Management focus on optimizing operating expenses and evaluating capital-raising alternatives to support ongoing working capital requirements.
•Ongoing clinical positioning of non-invasive cardiac mapping solutions to support physician decision-making in arrhythmia treatments.

Catalysts

•Quarterly financial reporting and ongoing revenue growth trajectory updates in upcoming earnings releases.
•Potential regulatory approvals or clearance milestones for new product iterations or international markets.
•Execution of strategic financing, debt restructuring, or capital-raising transactions to alleviate liquidity pressures.
•Expansion of hospital customer contracts and distribution partnerships accelerating product pull-through.
•Clinical data publications highlighting the efficacy and procedural benefits of Vdrive and non-invasive mapping systems.

Strengths

•High percentage revenue growth trajectory, evidenced by a 380.7% YoY increase in Q2 2026 revenue to $1,019,000.
•Innovative proprietary product portfolio addressing specialized needs in cardiac electrophysiology and arrhythmia treatment.
•Differentiated technology offerings aimed at reducing procedural radiation and enhancing catheter precision.
•Growing commercial traction and increasing hospital adoption metrics from a low baseline.
•Focused management commitment to expanding clinical utility and physician awareness in target cardiology markets.

Risks & Concerns for Catheter Precision Inc ($VTAK)

You're one step away

Unlock the full risk analysis

See business risks, AI filing insights, and deeper research for this stock. Create a free account to continue — includes a 14-day Pro trial.

No card required • Free plan stays after trial

About this summary

Summary generated on Oct 16, 2026.